The Clínica Universidad de Navarra (CUN), Pamplona, Spain, recently celebrated its tenth anniversary of using Yttrium-90 (Y-90) microsphere radioembolization for the treatment of liver cancer. CUN was a European pioneer in the use of radioembolization, or selective internal radiation therapy (SIRT) with SIR-Spheres microspheres and has treated over 400 patients using the procedure.
A prospective single-arm, five-year study has found that CT-guided percutaneous cryoablation for renal cell carcinoma offers very high efficacy, approaching that of the gold standard, surgery. Cryoablation also has a more favourable safety profile.
Hepatic Oncology is published by Future Medicine Ltd, and joins its portfolio of oncology journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.
Medtronic’s sham-controlled renal denervation study, SYMPLICITY HTN-3, has failed to meet its primary efficacy endpoint of significantly reducing office blood pressure between baseline and six months in patients with treatment-resistant hypertension and systolic blood pressure of ≥160mmHg.
The latest recommendations, jointly issued by the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Radiologists (RCR), has recently been published and are intended both for the National Health Service and the private sector.
An important opportunity has opened up for interventional oncologists as WCIO leaders take the helm of the E1208 trial. Michael C Soulen writes that the change in the trial leadership from medical oncology to interventional oncology represents a challenge because it rests on the question: can interventional oncologists run a successful cooperative group trial of image-guided therapy?
Medtronic has announced that the first patients were randomised in SYMPLICITY HTN-4, evaluating the Symplicity renal denervation system in patients with moderate uncontrolled hypertension (systolic blood pressure ≥140mmHg and <160mmHg, despite treatment with three or more antihypertensive medications of different classes).
At the recently concluded Radiological Society of North America (RSNA 1–6 December, Chicago, USA), Siemens introduced a new angiography system optimied for a broad clinical utilisation. Artis one is designed for routine interventions, which represent the majority of angiographic procedures. Energy consumption with the new system is up to 20% lower than with Artis zee floor.
Researchers from Oxford suggest that augmentation of the preclose technique (using Proglide from Abbott Vascular) with the Angio-Seal vascular closure device (St Jude Medical) is a safe and effective adjunct for haemostasis that increases the success of percutaneous endovascular aneurysm repair.
The MVP-5 system (Reverse Medical) is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, in 3–5mm vessels. The company also announced the first US clinical case along with the US FDA 510k clearance.
The trial evaluates eliminating coiling by using the anti-reflux Surefire Infusion System in radioembolization procedures in liver cancer.
The research and consulting firm GlobalData states that the global renal denervation market will witness significant growth over the next six years—jumping from $15.5m in 2012 to $171.7m by 2019 at a compound annual growth rate of 41%. It explains that the estimated growth is mainly due to the intervention’s expected approval in major countries.
Gore & Associates (Flagstaff, AZ) announced the launch of the Gore Acuseal vascular graft for vascular access. The Acuseal is designed for early cannulation within 24 hours after implantation and expands treatment options for earlier removal or possible avoidance of a central venous catheter, which is a major source of infection for hemodialysis patients. The US Food and Drug Administration cleared the Gore Acuseal vascular graft in April 2013.
Stenting of the renal artery appears to offer no significant improvement when added to medication-based therapy, according to results from the CORAL study presented at the American Heart Association (AHA) 2013 Scientific Sessions in Dallas, USA, on 18 November 2013. The findings appeared concurrently in the New England Journal of Medicine.
Volcano has announced the commercial release and initial implantations of its innovative Crux vena cava filter in patients at risk for recurrent pulmonary embolism. It is the only filter with a double helical design that self-centres to help prevent filter tilt and offers the Bi-Trieval option of retrieval via either the jugular or femoral vein.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos